Panel is a valuable tool for hypothesis generation and testing. BRAF is the most common melanoma mutation. Findings validate patient-derived tumor models. SAN FRANCISCO — Researchers have developed a new genetic screening tool that will aid in the investigation of possible treatments for patients...
Tue, Nov 15 2011
Filed under: Filed under: Press Releases, Research, Treatment, Conference, melanoma, Cancer, Media Materials, AACR, American Association for Cancer Research, mutations, genetics, screening, meeting, National Cancer Institute, NCI, skin cancer, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, panel, Dr. Heinz-Herbert Fiebig